Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

By Kellum A.   Jagiello-Gruszfeld A.   Bondarenko I.N.   Patwardhan R.   Messam C.   Mostafa Kamel Y.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2339-2346

Informa Healthcare

Access to resources Recommend Favorite

Optimum Dose of Once‐Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double‐Blind Trial Versus Placebo

By  

LUTS, Vol. 8, Iss. 3, 2016-09 ,pp. : 150-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of fasiglifam (TAK‐875), a G protein‐coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 675-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 242-250

John Wiley & Sons Inc

Access to resources Recommend Favorite